Navigation Links
Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference
Date:2/3/2009

The Company has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine), and it has advanced AZ-104 (Staccato loxapine) into Phase 2b testing, both product candidates being developed for the acute treatment of migraine headache. AZ-002 (Staccato alprazolam) has completed Phase 1 testing and a Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or oth
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. Signalife Provides Corporate Update
5. Biomira Announces Plan to Reincorporate in the United States
6. Pressure BioSciences, Inc. Provides Corporate Update
7. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
8. Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters
9. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, ... unmet medical needs using RNA-targeted technologies, today ... (RXI-109-1402) with RXI-109, for the reduction of ... revision surgery, has been initiated. ...
(Date:7/30/2014)... 30, 2014 Adding to their already ... boat special – Buy 2 of any Weighing ... will benefit lab technicians looking for durable and reliable ... ideal for multiple applications including weighing liquids, solid, or ... choices including diamond-shaped, hexagonal, square, aluminum weighing, and standard ...
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report Strategic ... report provides in-depth analysis of the current trends ... capital segments of the financial industry, bearing in ... impact on the future of emerging biotechnology companies ... identifies regions of the world that are attracting ...
(Date:7/29/2014)... 29, 2014 Human Longevity, Inc. (HLI), a ... on extending the healthy, high performance human life span, ... Ph.D., an expert in machine learning and machine translation ... HLI from Google where he was Distinguished Research Scientist ... directly to HLI Co-Founder and CEO, J. Craig ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Weighing Boat Promotion Now Available at Pipette.com, Major Pipette Distributor 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today ... up to $185 million in exchange for rights ... American sales of Lexiscan(TM),(regadenoson) injection. CV Therapeutics received ... receive a potential future milestone payment,of $10 million., ...
... and Families, EMERYVILLE, Calif., April 15 ... two new health care areas designed to,soothe patients ... to offer health resources. The Carol Ann,Read Breast ... procedures, all in one location, for the quickest ...
... April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, ... Dr. Anders,Kolb of the Nemours Center for Childhood ... Pediatric Sarcomas" was,presented today at the American Association ... being held in San Diego, California from,April 12-16, ...
Cached Biology Technology:CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 3Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 2Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 3Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
(Date:7/30/2014)... cells can develop into a multitude of cells types. Researchers ... the specific types of mature cells that make up the ... key seems to be long chains of sugars that dangle ... at the University of California, San Diego, has created synthetic ... can be more easily manipulated to direct the process, they ...
(Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... not be the first state that comes to mind. But it,s ... in Illinois and 1,500 acres of wine grapes. One acre ... though more commonly it,s $3,000 to $5,000. The largest wineries in ... 10,000 per year. "In many cases, growing wine grapes ...
... lacking access to clean, safe drinking water, scientists are ... new filtering technology that kills up to 98 percent ... A report on the technology appears in Nano ... Yi Cui and colleagues explain that most water ...
... new evidence that the fat tissue in those spare tires ... storage depot for surplus calories is an active organ ... perhaps increasing the risk of heart attacks, cancer, and other ... other substances not previously known to be secreted into the ...
Cached Biology News:Taming wild grapes for better wine 2Taming wild grapes for better wine 3
... UltraClean GelSpin Kit utilizes a silica based spin ... After electrophoresis, the desired DNA band is cut ... the spin filter unit. The gel slice is ... Then the DNA is bound to the silica ...
...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse polyclonal antibody to GRID2 - glutamate receptor, ionotropic, delta 2...
Biology Products: